ReutersUPDATE 1-Biogen, AbbVie drug slows MS episodes, safety issues recurReuters UK(Adds analyst comment, background on daclizumab, MS drugs, byline). By Ransdell Pierson. June 16 (Reuters) – A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by …Once-monthly MS drug from Biogen Idec, AbbVie clears Phase III hurdleFierceBiotechBiogen, AbbVie drug slows MS episodes, safety issues recurWTAQSuccessful Phase 3 results for daclizumabSeeking AlphaWall Street Journalall 16 news articles …Read Full Story
UPDATE 1-Biogen, AbbVie drug slows MS episodes, safety issues recur - Reuters UK
Real Estate of Cebu
